BMP signaling in osteogenesis, bone remodeling and repair

European Journal of Trauma

Volumn 31, Issue 5, 2005, Pages 464-479

  Valcourt, Ulrich ^a   Moustakas, Aristidis ^b,c  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UPPSALA UNIVERSITY   (Sweden)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Sweden)

Author keywords

BMP; Bone; Chondrogenesis; Osteogenesis; Smad TGF

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN RECEPTOR; COLLAGEN TYPE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NOGGIN; NUCLEAR FACTOR; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOGENIC PROTEIN 1; OSTEOPONTIN; PARATHYROID HORMONE RELATED PROTEIN; PROTEIN; SCLEROSTIN; SIALOPROTEIN; SMAD PROTEIN; SMAD1 PROTEIN; SMAD6 PROTEIN; SMAD7 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR DLX5; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN; UNCLASSIFIED DRUG; YING YANG 1 PROTEIN;

ADIPOCYTE; AUTOSOMAL RECESSIVE DISORDER; BONE DEVELOPMENT; BONE DISEASE; BONE DYSPLASIA; BONE REMODELING; CARTILAGE CELL; CELL DIFFERENTIATION; GENE MUTATION; GENE OVEREXPRESSION; HOMEOSTASIS; HUMAN; MUSCLE CELL; OSTEOBLAST; OSTEOCLAST; OVARIECTOMY; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 26944450918     PISSN: 14390590     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00068-005-2049-1     Document Type: Review

References (131)

1. Olsen BR, Reginato AM, Wang W. Bone development. Annu Rev Cell Dev Biol 2000;16:191-220.
2. Karsenty G, Wagner EF. Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2002;2:389-406.
3. Yoon BS, Lyons KM. Multiple functions of BMPs in chondrogenesis. J Cell Biochem 2004;93:93-103.
4. Reddy SV. Regulatory mechanisms operative in osteoclasts. Crit Rev Eukaryot Gene Expr 2004;14:255-70.
5. Wittrant Y, Theoleyre S, Chipoy C, et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 2004;1704:49-57.
6. Margolis RN, Canalis E, Partridge NC. Anabolic hormones in bone: basic research and therapeutic potential. J Clin Endocrinol Metab 1996;81:872-7.
7. Canalis E, Economides AN, Gazzerro E. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 2003;24:218-35.
8. Wan M, Cao X. BMP signalling in skeletal development. Biochem Biophys Res Commun 2005;328:651-7.
9. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 2003;425:577-84.
10. Miyazawa K, Shinozaki M, Hara T, et al. Two major Smad pathways in TGF-β superfamily signalling. Genes Cells 2002;7:1191-204.
11. Moustakas A, Souchelnytskyi S, Heldin C-H. Smad regulation in TGF-β signal transduction. J Cell Sci 2001;114:4359-69.
12. Shi Y, Massagué J. Mechanisms of TGF-β signalling from cell membrane to the nucleus. Cell 2003;113:685-700.
13. Sampath TK, Maliakal JC, Hauschka PV, et al. Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J Biol Chem 1992;267:20352-62.
14. Wang EA, Rosen V, Cordes P, et al. Purification and characterization of other distinct bone-inducing factors. Proc Natl Acad Sci U S A 1988;85:9484-8.
15. Wozney JM, Rosen V, Celeste AJ, et al. Novel regulators of bone formation: molecular clones and activities. Science 1988;242:1528-34.
16. Ten Dijke P, Korchynskyi O, Valdimarsdottir G, et al. Controlling cell fate by bone morphogenetic protein receptors. Mol Cell Endocrinol 2003;211:105-13.
17. Miyazono K, Maeda S, Imamura T. Coordinate regulation of cell growth and differentiation by TGF-β superfamily and Runx proteins. Oncogene 2004;23:4232-7.
18. Mundlos S, Otto F, Mundlos C, et al. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 1997;89:773-9.
19. Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997;89:755-64.
20. Otto F, Thornell AP, Crompton T, et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997;89:765-71.
21. Ducy P, Zhang R, Geoffroy V, et al. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997;89:747-54.
22. Kern B, Shen J, Starbuck M, Karsenty G. Cbfa1 contributes to the osteoblast-specific expression of type I collagen genes. J Biol Chem 2001;276:7101-7.
23. Ducy P, Starbuck M, Priemel M, et al. A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev 1999;13:1025-36.
24. Lee K-S, Kim H-J, Li Q-L, et al. Runx2 is a common target of transforming growth factor β1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol 2000;20:8783-92.
25. Miyama K, Yamada G, Yamamoto TS, et al. A BMP-inducible gene, dlx5, regulates osteoblast differentiation and mesoderm induction. Dev Biol 1999;208:123-33.
26. Lee MH, Kim Y-J, Kim H-J, et al. BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-β1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression. J Biol Chem 2003;278:34387-94.
27. Zhang YW, Yasui N, Ito K, et al. A RUNX2/PEBP2alpha A/CBFA1 mutation displaying impaired transactivation and Smad interaction in cleidocranial dysplasia. Proc Natl Acad Sci U S A 2000;97:10549-54.
28. Zaidi SK, Sullivan AJ, van Wijnen AJ, et al. Integration of Runx and Smad regulatory signals at transcriptionally active subnuclear sites. Proc Natl Acad Sci U S A 2002;99:8048-53.
29. Lee MH, Javed A, Kim H-J, et al. Transient upregulation of CBFA1 in response to bone morphogenetic protein-2 and transforming growth factor β1 in C2C12 myogenic cells coincides with suppression of the myogenic phenotype but is not sufficient for osteoblast differentiation. J Cell Biochem 1999;73:114-25.
30. Katagiri T, Yamaguchi A, Komaki M, et al. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol 1994;127:1755-66.
31. Alliston T, Choy L, Ducy P, et al. TGF-β-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J 2001;20:2254-72.
32. Tribioli C, Lufkin T. The murine Bapx1 homeobox gene plays a critical role in embryonic development of the axial skeleton and spleen. Development 1999;126:5699-711.
33. Satokata I, Maas R. Msx1 deficient mice exhibit cleft palate and abnormalities of craniofacial and tooth development. Nat Genet 1994;6:348-56.
34. Satokata I, Ma L, Ohshima H, et al. Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation. Nat Genet 2000;24:391-5.
35. Nakashima K, Zhou X, Kunkel G, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002;108:17-29.
36. Lee M-H, Kwon TG, Park HS, et al. BMP-2-induced Osterix expression is mediated by Dlx5 but is independent of Runx2. Biochem Biophys Res Commun 2003;309:689-94.
37. Yagi K, Tsuji K, Nifuji A, et al. Bone morphogenetic protein-2 enhances osterix gene expression in chondrocytes. J Cell Biochem 2003;88:1077-83.
38. Wan M, Shi X, Feng X, et al. Transcriptional mechanisms of bone morphogenetic protein-induced osteoprotegrin gene expression. J Biol Chem 2001;276:10119-25.
39. Itoh K, Udagawa N, Katagiri T, et al. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-κB ligand. Endocrinology 2001;142:3656-62.
40. Kaneko H, Arakawa T, Mano H, et al. Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts. Bone 2000;27:479-86.
41. De Luca F, Barnes KM, Uyeda JA, et al. Regulation of growth plate chondrogenesis by bone morphogenetic protein-2. Endocrinology 2001;142:430-6.
42. Yoon BS, Ovchinnikov DA, Yoshii I, et al. Bmpr1a and Bmpr1b have overlapping functions and are essential for chondrogenesis in vivo. Proc Natl Acad Sci U S A 2005;102:5062-7.
43. Valcourt U, Gouttenoire J, Moustakas A, et al. Functions of transforming growth factor-β family type I receptors and Smad proteins in the hypertrophic maturation and osteoblastic differentiation of chondrocytes. J Biol Chem 2002;277:33545-58.
44. Zehentner BK, Dony C, Burtscher H. The transcription factor Sox9 is involved in BMP-2 signalling. J Bone Miner Res 1999;14:1734-41.
45. Krishnan V, Ma Y, Moseley J, et al. Bone anabolic effects of sonic/indian hedgehog are mediated by bmp-2/4-dependent pathways in the neonatal rat metatarsal model. Endocrinology 2001;142:940-7.
46. Minina E, Wenzel HM, Kreschel C, et al. BMP and Ihh/PTHrP signalling interact to coordinate chondrocyte proliferation and differentiation. Development 2001;128:4523-34.
47. Minina E, Kreschel C, Naski MC, et al. Interaction of FGF, Ihh/PthIh, and BMP signalling integrates chondrocyte proliferation and hypertrophic differentiation. Dev Cell 2002;3:439-49.
48. Zhang D, Schwarz EM, Rosier RN, et al. ALK2 functions as a BMP type I receptor and induces Indian hedgehog in chondrocytes during skeletal development. J Bone Miner Res 2003;18:1593-604.
49. Seki K, Hata A. Indian hedgehog gene is a target of the bone morphogenetic protein signalling pathway. J Biol Chem 2004;279:18544-9.
50. Murtaugh LC, Zeng L, Chyung JH, et al. The chick transcriptional repressor Nkx3.2 acts downstream of Shh to promote BMP-dependent axial chondrogenesis. Dev Cell 2001;1:411-22.
51. Kim DW, Lassar AB. Smad-dependent recruitment of a histone deacetylase/Sin3A complex modulates the bone morphogenetic protein-dependent transcriptional repressor activity of Nkx3.2. Mol Cell Biol 2003;23:8704-17.
52. Lengner CJ, Hassan MQ, Serra RW, et al. Nkx3.2 mediated repression of RUNX2 promotes chondrogenic differentiation. J Biol Chem 2005;280:15872-9.
53. Zeng L, Kempf H, Murtaugh LC, et al. Shh establishes an Nkx3.2/Sox9 autoregulatory loop that is maintained by BMP signals to induce somitic chondrogenesis. Genes Dev 2002;16:1990-2005.
54. Souchelnytskyi S, Moustakas A, Heldin C-H. TGF-β signalling from a three-dimensional perspective: insight into selection of partners. Trends Cell Biol 2002;12:304-7.
55. Piek E, Heldin C-H, ten Dijke P. Specificity, diversity, and regulation in TGF-β superfamily signalling. FASEB J 1999;13:2105-24.
56. De Robertis EM, Kuroda H. Dorsal-ventral patterning and neural induction in Xenopus embryos. Annu Rev Cell Dev Biol 2004;20:285-308.
57. Onichtchouk D, Chen YG, Dosch R, et al. Silencing of TGF-β signalling by the pseudoreceptor BAMBI. Nature 1999;401:480-5.
58. Zuzarte-Luis V, Montero JA, Rodriguez-Leon J, et al. A new role for BMP5 during limb development acting through the synergic activation of Smad and MAPK pathways. Dev Biol 2004;272:39-52.
59. Izzi L, Attisano L. Regulation of the TGFβ signalling pathway by ubiquitin-mediated degradation. Oncogene 2004;23:2071-8.
60. Nohe A, Keating E, Knaus P, et al. Signal transduction of bone morphogenetic protein receptors. Cell Signal 2004;16:291-9.
61. Gallea S, Lallemand F, Atfi A, et al. Activation of mitogen-activated protein kinase cascades is involved in regulation of bone morphogenetic protein-2-induced osteoblast differentiation in pluripotent C2C12 cells. Bone 2001;28:491-8.
62. Guicheux J, Lemonnier J, Ghayor C, et al. Activation of p38 mitogen-activated protein kinase and c-Jun-NH2-terminal kinase by BMP-2 and their implication in the stimulation of osteoblastic cell differentiation. J Bone Miner Res 2003;18:2060-8.
63. Lai CF, Cheng SL. Signal transductions induced by bone morphogenetic protein-2 and transforming growth factor-β in normal human osteoblastic cells. J Biol Chem 2002;277:15514-22.
64. Vinals F, Lopez-Rovira T, Rosa JL, et al. Inhibition of PI3K/p70 S6K and p38 MAPK cascades increases osteoblastic differentiation induced by BMP-2. FEBS Lett 2002;510:99-104.
65. Xiao G, Gopalakrishnan R, Jiang D, et al. Bone morphogenetic proteins, extracellular matrix, and mitogen-activated protein kinase signalling pathways are required for osteoblast-specific gene expression and differentiation in MC3T3-E1 cells. J Bone Miner Res 2002;17:101-10.
66. Lee KS, Hong SH, Bae SC. Both the Smad and p38 MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factor-β and bone morphogenetic protein. Oncogene 2002;21:7156-63.
67. Lee YS, Chuong CM. Activation of protein kinase A is a pivotal step involved in both BMP-2- and cyclic AMP-induced chondrogenesis. J Cell Physiol 1997;170:153-65.
68. Noth U, Tuli R, Seghatoleslami R, et al. Activation of p38 and Smads mediates BMP-2 effects on human trabecular bone-derived osteoblasts. Exp Cell Res 2003;291:201-11.
69. Seto H, Kamekura S, Miura T, et al. Distinct roles of Smad pathways and p38 pathways in cartilage-specific gene expression in synovial fibroblasts. J Clin Invest 2004;113:718-26.
70. Nohe A, Hassel S, Ehrlich M, et al. The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signalling pathways. J Biol Chem 2002;277:5330-8.
71. Sammar M, Stricker S, Schwabe GC, et al. Modulation of GDF5/BRI-b signalling through interaction with the tyrosine kinase receptor Ror2. Genes Cells 2004;9:1227-38.
72. Zimmerman LB, De Jesus-Escobar JM, Harland RM. The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. Cell 1996;86:599-606.
73. Brunet LJ, McMahon JA, McMahon AP, et al. Noggin, cartilage morphogenesis, and joint formation in the mammalian skeleton. Science 1998;280:1455-7.
74. Devlin RD, Du Z, Pereira RC, et al. Skeletal overexpression of noggin results in osteopenia and reduced bone formation. Endocrinology 2003;144:1972-8.
75. Gazzerro E, Du Z, Devlin RD, et al. Noggin arrests stromal cell differentiation in vitro. Bone 2003;32:111-9.
76. Abe E, Yamamoto M, Taguchi Y, et al. Essential requirement of BMPs-2/4 for both osteoblast and osteoclast formation in murine bone marrow cultures from adult mice: antagonism by noggin. J Bone Miner Res 2000;15:663-73.
77. Gazzerro E, Gangji V, Canalis E. Bone morphogenetic proteins induce the expression of noggin, which limits their activity in cultured rat osteoblasts. J Clin Invest 1998;102:2106-14.
78. Pereira RC, Economides AN, Canalis E. Bone morphogenetic proteins induce gremlin, a protein that limits their activity in osteoblasts. Endocrinology 2000;141:4558-63.
79. Topol LZ, Bardot B, Zhang Q, et al. Biosynthesis, post-translation modification, and functional characterization of Drm/Gremlin. J Biol Chem 2000;275:8785-93.
80. Khokha MK, Hsu D, Brunet LJ, et al. Gremlin is the BMP antagonist required for maintenance of Shh and Fgf signals during limb patterning. Nat Genet 2003;34:303-7.
81. Gazzerro E, Pereira RC, Jorgetti V, et al. Skeletal overexpression of gremlin impairs bone formation and causes osteopenia. Endocrinology 2005;146:655-65.
82. Winkler DG, Sutherland MK, Geoghegan JC, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003;22:6267-76.
83. Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001;10:537-43.
84. Sutherland MK, Geoghegan JC, Yu C, et al. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 2004;35:828-35.
85. Winkler DG, Yu C, Geoghegan JC, et al. Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex. J Biol Chem 2004;279:36293-8.
86. Imamura T, Takase M, Nishihara A, et al. Smad6 inhibits signalling by the TGF-β superfamily. Nature 1997;389:622-6.
87. Nakao A, Afrakhte M, Morén A, et al. Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling. Nature 1997;389:631-5.
88. Hata A, Lagna G, Massagué J, et al. Smad6 inhibits BMP/Smad1 signalling by specifically competing with the Smad4 tumor suppressor. Genes Dev 1998;12:186-97.
89. Bai S, Shi X, Yang X, et al. Smad6 as a transcriptional corepressor. J Biol Chem 2000;275:8267-70.
90. Zhu H, Kavsak P, Abdollah S, et al. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature 1999;400:687-93.
91. Zhang Y, Chang C, Gehling DJ, et al. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc Natl Acad Sci U S A 2001;98:974-9.
92. Ebisawa T, Fukuchi M, Murakami G, et al. Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J Biol Chem 2001;276:12477-80.
93. Murakami G, Watabe T, Takaoka K, et al. Cooperative inhibition of bone morphogenetic protein signalling by Smurf1 and inhibitory Smads. Mol Biol Cell 2003;14:2809-17.
94. Zhao M, Qiao M, Oyajobi BO, et al. E3 ubiquitin ligase Smurf1 mediates core-binding factor α1/Runx2 degradation and plays a specific role in osteoblast differentiation. J Biol Chem 2003;278:27939-44.
95. Garrett IR, Chen D, Gutierrez G, et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 2003;111:1771-82.
96. Zhao M, Qiao M, Harris SE, et al. Smurf1 inhibits osteoblast differentiation and bone formation in vitro and in vivo. J Biol Chem 2004;279:12854-9.
97. Ying SX, Hussain ZJ, Zhang YE. Smurf1 facilitates myogenic differentiation and antagonizes the bone morphogenetic proteins-induced osteoblast conversion by targeting Smad5 for degradation. J Biol Chem 2003;278:39029-36.
98. Massagué J, Wotton D. Transcriptional control by the TGF-β/Smad signalling system. EMBO J 2000;19:1745-54.
99. Miyazono K, Kusanagi K, Inoue H. Divergence and convergence of TGF-β/BMP signalling. J Cell Physiol 2001;187:265-76.
100. Luo K, Stroschein SL, Wang W, et al. The Ski oncoprotein interacts with the Smad proteins to repress TGFβ signalling. Genes Dev 1999;13:2196-206.
101. Wang W, Mariani FV, Harland RM, et al. Ski represses bone morphogenic protein signalling in Xenopus and mammalian cells. Proc Natl Acad Sci U S A 2000;97:14394-9.
102. Berk M, Desai SY, Heyman HC, et al. Mice lacking the ski proto-oncogene have defects in neurulation, craniofacial, patterning, and skeletal muscle development. Genes Dev 1997;11:2029-39.
103. Shinagawa T, Ishii S. Generation of Ski-knockdown mice by expressing a long double-strand RNA from an RNA polymerase II promoter. Genes Dev 2003;17:1340-5.
104. Lana DP, Leferovich JM, Kelly AM, et al. Selective expression of a ski transgene affects IIb fast muscles and skeletal structure. Dev Dyn 1996;205:13-23.
105. Postigo AA. Opposing functions of ZEB proteins in the regulation of the TGFβ/BMP signalling pathway. EMBO J 2003;22:2443-52.
106. Tylzanowski P, Verschueren K, Huylebroeck D, et al. Smad-interacting protein 1 is a repressor of liver/bone/kidney alkaline phosphatase transcription in bone morphogenetic protein-induced osteogenic differentiation of C2C12 cells. J Biol Chem 2001;276:40001-7.
107. Postigo AA, Depp JL, Taylor JJ, et al. Regulation of Smad signalling through a differential recruitment of coactivators and corepressors by ZEB proteins. EMBO J 2003;22:2453-62.
108. Kurisaki K, Kurisaki A, Valcourt U, et al. Nuclear factor YY1 inhibits transforming growth factor β- and bone morphogenetic protein-induced cell differentiation. Mol Cell Biol 2003;23:4494-510.
109. Yoshida Y, Tanaka S, Umemori H, et al. Negative regulation of BMP/Smad signalling by Tob in osteoblasts. Cell 2000;103:1085-97.
110. Usui M, Yoshida Y, Yamashita T, et al. Enhancing effect of Tob deficiency on bone formation is specific to bone morphogenetic protein-induced osteogenesis. J Bone Miner Res 2002;17:1026-33.
111. Yoshida Y, Bubnoff A von, Ikematsu N, et al. Tob proteins enhance inhibitory Smad-receptor interactions to repress BMP signalling. Mech Dev 2003;120:629-37.
112. Zhang H, Bradley A. Mice deficient for BMP2 are nonviable and have defects in amnion/chorion and cardiac development. Development 1996;122:2977-86.
113. Winnier G, Blessing M, Labosky PA, et al. Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. Genes Dev 1995;9:2105-16.
114. Tremblay KD, Dunn NR, Robertson EJ. Mouse embryos lacking Smadi signals display defects in extra-embryonic tissues and germ cell formation. Development 2001;128:3609-21.
115. Yang X, Castilla LH, Xu X, et al. Angiogenesis defects and mesenchymal apoptosis in mice lacking SMAD5. Development 1999;126:1571-80.
116. Mishina Y, Suzuki A, Ueno N, et al. Bmpr encodes a type I bone morphogenetic protein receptor that is essential for gastrulation during mouse embryogenesis. Genes Dev 1995;9:3027-37.
117. Yi SE, Daluiski A, Pederson R, et al. The type I BMP receptor BMPRIB is required for chondrogenesis in the mouse limb. Development 2000;127:621-30.
118. Luo G, Hofmann C, Bronckers AL, et al. BMP-7 is an inducer of nephrogenesis, and is also required for eye development and skeletal patterning. Genes Dev 1995;9:2808-20.
119. Dewulf N, Verschueren K, Lonnoy O, et al. Distinct spatial and temporal expression patterns of two type I receptors for bone morphogenetic proteins during mouse embryogenesis. Endocrinology 1995;136:2652-63.
120. Mishina Y, Starbuck MW, Gentile MA, et al. Bone morphogenetic protein type IA receptor signalling regulates postnatal osteoblast function and bone remodelling. J Biol Chem 2004;279:27560-6.
121. Zhao M, Harris SE, Horn D, et al. Bone morphogenetic protein receptor signalling is necessary for normal murine postnatal bone formation. J Cell Biol 2002;157:1049-60.
122. Turgeman G, Zilberman Y, Zhou S, et al. Systemically administered rhBMP-2 promotes MSC activity and reverses bone and cartilage loss in osteopenic mice. J Cell Biochem 2002;86:461-74.
123. Bouxsein ML, Turek TJ, Blake CA, et al. Recombinant human bone morphogenetic protein-2 accelerates healing in a rabbit ulnar osteotomy model. J Bone Joint Surg Am 2001;83:1219-30.
124. Cook SD, Wolfe MW, Salkeld SL, et al. Effect of recombinant human osteogenic protein-1 on healing of segmental defects in non-human primates. J Bone Joint Surg Am 1995;77:734-50.
125. Gerhart TN, Kirker-Head CA, Kriz MJ, et al. Healing segmental femoral defects in sheep using recombinant human bone morphogenetic protein. Clin Orthop 1993;293:317-26.
126. Heckman JD, Ehler W, Brooks BP, et al. Bone morphogenetic protein but not transforming growth factor-β enhances bone formation in canine diaphyseal nonunions implanted with a biodegradable composite polymer. J Bone Joint Surg Am 1999;81:1717-29.
127. Rundle CH, Miyakoshi N, Kasukawa Y, et al. In vivo bone formation in fracture repair induced by direct retroviral-based gene therapy with bone morphogenetic protein-4. Bone 2003;32:591-601.
128. Geesink RG, Hoefnagels NH, Bulstra SK. Osteogenic activity of OP-1 bone morphogenetic protein (BMP-7) in a human fibular defect. J Bone Joint Surg Br 1999;81:710-8.
129. Pecina M, Giltaij LR, Vukicevic S. Orthopaedic applications of osteogenic protein-1 (BMP-7). Int Orthop 2001;25:203-8.
130. Khan SN, Lane JM. The use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in orthopaedic applications. Expert Opin Biol Ther 2004;4:741-8.
131. Baltzer AW, Lieberman JR. Regional gene therapy to enhance bone repair. Gene Ther 2004;11:344-50.